Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
688.49B
Market cap688.49B
Price-Earnings ratio
43.35
Price-Earnings ratio43.35
Dividend yield
1.85%
Dividend yield1.85%
Average volume
7.77M
Average volume7.77M
High today
$288.11
High today$288.11
Low today
$283.63
Low today$283.63
Open price
$285.03
Open price$285.03
Volume
6.29M
Volume6.29M
52 Week high
$288.11
52 Week high$288.11
52 Week low
$193.55
52 Week low$193.55

Stock Snapshot

With a market cap of 688.49B, Johnson & Johnson(JNJ) trades at $286.67. The stock has a price-to-earnings ratio of 43.35 and currently yields dividends of 1.85%.

On 2026-11-14, Johnson & Johnson(JNJ) stock traded between a low of $283.63 and a high of $288.11. Shares are currently priced at $286.67, which is +1.1% above the low and -0.5% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 6.29M, against a daily average of 7.77M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $288.11 and a 52-week low of $193.55.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $288.11 and a 52-week low of $193.55.

JNJ News

NPR 2h
Legal scholar Stephen Vladeck on Texas' new Democratic AG and federal litigation - NPR

...

Legal scholar Stephen Vladeck on Texas' new Democratic AG and federal litigation - NPR
Simply Wall St 6h
Johnson & Johnson Backs Prostate Cancer Device Development

Johnson & Johnson (NYSE: JNJ) agreed to invest in Francis Medical to support development of the Vanquish prostate cancer ablation device. The Vanquish system i...

Johnson & Johnson Backs Prostate Cancer Device Development
24/7 Wall St. 24h
I Bonds Pay 5.51%. Here's What Dividend Investors Should Know

Investing I Bonds Pay 5.51%. Here’s What Dividend Investors Should Know By Chris Lange 𝕏 f ⧉ Quick Read Johnson & Johnson (NYSE:JNJ) yields about 2%, well below...

I Bonds Pay 5.51%. Here's What Dividend Investors Should Know

Analyst ratings

67%

of 27 ratings
Buy
66.7%
Hold
25.9%
Sell
7.4%

More JNJ News

TipRanks 1d
GH Research appoints Vanina Popova as chief development officer

GH Research (GHRS) announced the appointment of Vanina Popova as chief development officer, to lead the clinical development of GH001 into our pivotal programs...

24/7 Wall St. 1d
How Much Does a 69-Year-Old Need Invested in Dividend Stocks to Collect $3,000 a Month?

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

How Much Does a 69-Year-Old Need Invested in Dividend Stocks to Collect $3,000 a Month?
Simply Wall St 1d
Johnson & Johnson Was Ordered To Pay $3.3 Million In Massachusetts

Johnson & Johnson (NYSE:JNJ) was ordered to pay a $3.3 million verdict in a Massachusetts mesothelioma case linked to baby powder. The jury decision adds to a...

Johnson & Johnson Was Ordered To Pay $3.3 Million In Massachusetts
TipRanks 2d
J&J Analyst Maintains $275 Price Target as Icotyde’s PsA Data Support Launch but Offer Limited Upside

Analyst Jason Gerberry from Bank of America Securities reiterated a Hold rating on Johnson & Johnson and keeping the price target at $275.00. Jason Gerberry’s...

The Motley Fool 3d
These 5 Dividend Aristocrats® Have Raised Payouts for Decades

What do Coca-Cola (KO +0.68%), Procter & Gamble (PG -0.59%), Johnson & Johnson (JNJ -0.13%), PepsiCo (PEP +0.23%), and Colgate-Palmolive (CL -0.09%) have in com...

These 5 Dividend Aristocrats® Have Raised Payouts for Decades
The Motley Fool 3d
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

Johnson & Johnson (JNJ -0.28%) has made significant business changes over the past few years. Perhaps the most notable was the company's decision to spin off it...

Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
Simply Wall St 3d
Does Johnson & Johnson Have A New Growth Driver In Bipolar Mania?

Johnson & Johnson (NYSE:JNJ) reported positive topline results from a second pivotal Phase 3 trial of CAPLYTA for bipolar I mania. The study in adults with bip...

Does Johnson & Johnson Have A New Growth Driver In Bipolar Mania?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.